参考文献：Kien Hung Do et al, PD-L1-negative non-small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature, Respirol Case Rep. 2023 May 3.
3. Ramalingam SS, CIuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. J Clin Oncol. 2020;38(suppl 15):9500-9500. doi:10.1200/JCO.2020.3...
EMPOWER-Lung 3和CheckMate 9LA更新 此外,来自II期EMPOWER-Lung 3研究(NCT03409614)第二部分的2年随访数据显示,在PD-L1表达低于1%的患者中,联合使用cemiplimab与单独化疗相比,生存率更高(HR, 0.73;95% CI, 0.50-1.08), 1% - 49%PDL1表达 (HR,...
EMPOWER-Lung 3和CheckMate 9LA更新 此外,来自II期EMPOWER-Lung 3研究(NCT03409614)第二部分的2年随访数据显示,在PD-L1表达低于1%的患者中,联合使用cemiplimab与单独化疗相比,生存率更高(HR, 0.73;95% CI, 0.50-1.08), 1% - 49%PDL1表达 (HR, 0.48;95% CI, 0.34-0.68), 50%或更高PDL1表达(HR, 0.4...
Here we report the role of CGS pathway in NSCLC tumors that are both PDL1-negative and TMB-Low.Methods:DNA (592-gene or whole exome) and RNA sequencing (whole transcriptome) was performed for NSCLC specimens (n=7264) submitted to Caris Life Sciences (Phoenix, AZ). PDL1 negativity was ...
GC patients with high level PDL1 expression in tumor cells or in immune cells were both associated with better survival compared with those with negative expression (5-year OS, 61% vs. 48%, P = 0.000, and 55% vs. 45%, P < 0.0001, respectively). As con... 展开 关键词: gastric ...
[17]Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer 肝细胞癌: (1)肝癌患者PBMC中PD-1、PD-L1和PD-L2分子表达增加,且PD-1、PD-L1与IFN-γ水平有关联,提示PD-1和PD-L1与肿瘤的发展以及肿瘤细胞的免疫逃逸有关。 [18]刘伟,柴琳,粱军利, et ...
21 Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 2019, 393(10183): 1819-1830. doi: 10.1...
PD-L1≥50%PD-L1Negative PD-L1Negative (Nomembranousstaining) GainorJFetal,JClinOncol33,2015(abstr8012) Ph3programwithAtezoin1LNSCLC IMpower150Atezo+Carbo+Pac Non-squamousAtezo+Carbo+Pac+Avastin2017(PFS) n1200Carbo+Pac+Avastin IMpower130Atezo+Carbo+Nab-pac ...
The purpose of this study was to elucidate the regulation of programmed death ligand 1 (PDL1), lactate dehydrogenase A (LDHA) and miR-34a in triple negative breast cancer (TNBC) and to explore the function and mechanism of PDL1 and LDHA as competitive endogenous RNAs (ceRNAs) in TNBC via...